Krystal(US:KRYS) Financial Modeling Prep·2026-02-17 20:00Financial Performance - Krystal Biotech reported earnings per share of $1.70, surpassing the estimated $1.62 [1][6] - The company achieved revenue of approximately $107.1 million, exceeding the estimated $105.1 million [1][6] - Revenue from VYJUVEK contributed to a total of $730.3 million since its U.S. launch [2][6] Liquidity and Financial Stability - The company ended the quarter with $955.9 million in cash and investments, indicating a strong liquidity position [3][6] - A current ratio of 10.14 suggests the company can easily cover its short-term liabilities [3] - The low debt-to-equity ratio of 0.0084 indicates minimal reliance on debt, providing financial stability [3] Valuation Metrics - The company's P/E ratio is 40.22, and the price-to-sales ratio is 21.47, reflecting investor confidence in its growth potential [4] - The enterprise value to sales ratio is 20.44, and the enterprise value to operating cash flow ratio is 43.30, highlighting a positive market outlook [4] - An earnings yield of 2.49% indicates a return on investment based on earnings [4] Strategic Focus and Future Goals - The company aims to support patients with dystrophic epidermolysis bullosa globally and plans to launch multiple products by 2030 [5] - Krystal Biotech intends to treat over 10,000 patients with rare diseases by 2030 [5] - Recent developments in cystic fibrosis research underscore the versatility of the company's approach [5]